Policy
Regulation, payment and the standards that govern longevity care.
FDA puts a major GLP-1 compounder on notice
In a September 18 warning letter, FDA said Empower Pharmacy appeared to compound semaglutide and tirzepatide products that were essentially copies of approved drugs in substantial quantities.
$16.4 trillion: the economic case for prevention
A McKinsey Health Institute and Abu Dhabi Future Health whitepaper models an upper-bound scenario in which eliminating modifiable behavioral, metabolic, and environmental risks could add $16.4 trillion to annual global GDP in 2050.
Deepfake doctors are selling pills
CBC reports that AI-generated ads using the faces and voices of prominent Canadian physicians are circulating on Facebook and TikTok, selling prostate treatments, joint pills and “$1 million satisfaction guarantees.” Dr.
Bill Targets Corporate Control of Doctors
The Stop Corporate Takeovers of Physicians Act, introduced Sept 16 by Senators Warren, Wyden and Merkley, would bar private equity, insurers and other non-physician-controlled businesses from owning or directing medical practices.
FDA opens the file on testosterone for menopause
On Sept 17, FDA’s Office of Women’s Health and Center for Drug Evaluation and Research (CDER) held a public workshop on testosterone use in menopausal women: benefits, dosing, lab interpretation and long-term safety, with the stated aim of informing research and drug development.
FDA advisory committee recommends six peptides for compounding
The question at hand was never whether these compounds should be FDA approved. It was whether a licensed 503A compounding pharmacy should be legally permitted to prepare them for an individual patient holding a valid prescription from a licensed clinician.
The Sunday edition.
The week in longevity medicine, every Sunday.
Free, delivered by Substack. Unsubscribe any time.